USPTO Patent Applications - Peptides (C07K)

Patent Application: Cancer Treatment Compositions and Methods

The USPTO has published a new patent application (US20260085120A1) for compositions and methods related to cancer treatment. The application describes binding agents, carrier proteins, and therapeutic agents, particularly for cancers expressing PD-LI or PD-L2, and lyophilized compositions.

Patent Application for Treating Cancer with Anti-CTLA4 Antibodies

The USPTO has published a new patent application (US20260085119A1) from ADAGENE PTE. LTD. for methods of treating cancers using anti-CTLA4 antibodies. The application details compositions and treatment methods, including combination therapies for cancers resistant to PD-1 or PD-L1 inhibitors.

Anti-CTLA-4 Antibody Conjugate Activated by Tumor Microenvironment

The USPTO has published a patent application (US20260085118A1) for a novel conjugate of an anti-CTLA-4 antibody activated by the tumor microenvironment. The application details a dual-activated conjugate designed to improve targeting efficacy, overcome drug resistance, and reduce toxicity.

Antibodies with chimeric constant domains reduce effector functions

The USPTO has published a patent application (US20260085117A1) detailing antibodies with chimeric constant domains designed to reduce effector functions. The application, filed on November 24, 2025, describes recombinant polypeptides and methods for their production.

Patent Application: Antibody Heavy Chain Regions Reduce Fc Gamma Receptor Binding

The USPTO has published a patent application (US20260085116A1) detailing antibody heavy chain constant regions modified to reduce binding to Fc gamma receptors. This modification, achieved through specific residue replacements or deletions in the hinge region, aims to decrease effector functions in antibodies and Fc fusion proteins.

CD3 Binding Antibodies Patent Application Inventors Listed

The USPTO has published a new patent application, US20260085115A1, related to CD3 binding antibodies. The application, filed on June 2, 2025, lists inventors Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, and Duy Pham.

Anti-GPRC5D Antibody for Cancer Treatment

The USPTO has published a patent application (US20260085114A1) filed by Kyinno Biotechnology Co., Ltd. The application describes an anti-G protein-coupled receptor family class C group 5 member D (GPRC5D) antibody or fragment thereof for the treatment of tumors or cancers. It also details a bispecific antibody targeting GPRC5D and CD3.

Cell Culture Method Suppressing Foam Aggregates

The USPTO has published a new patent application (US20260085282A1) from FUJIFILM Corporation detailing a cell culture method. The method aims to suppress foam aggregate formation by adjusting poloxamer concentration or foam liquid viscosity during cell culture at high densities.

Karyocreate Patent Application US20260085330A1 Details CRISPR Technology

The USPTO has published patent application US20260085330A1 from Karyocreate detailing CRISPR technology for inducing aneuploidy. The application, filed on September 8, 2023, describes fusion proteins and guide RNAs that interfere with chromosome segregation.

Patent Application for Endoglin Antibodies Detecting Cancer Splice Variants

The USPTO has published a patent application (US20260086096A1) for endoglin antibodies designed to detect cancer splice variants. The application, filed by Nam Yong Lee, details methods and compositions for improved cancer diagnosis.

Metabolic Selection via Serine Biosynthesis Pathway Patent Application

The USPTO has published a new patent application, US20260085327A1, related to metabolic selection via the serine biosynthesis pathway. The application details an isolated mammalian cell with reduced expression of Phosphoserine Phosphatase (PSPH) and its use in recombinant protein production.

Base Editing of Plant Cell Organelle DNA

The USPTO has published a patent application (US20260085323A1) detailing a method for base editing plant cell organelle DNA. The application, filed by the Institute for Basic Science, describes a composition and method for editing adenine to guanine and cytosine to thymine in plant cell organelle DNA.

USPTO Patent Application for Fusion Polypeptides

The USPTO has published a new patent application (US20260085300A1) detailing systems and compositions for fusion polypeptides and their methods of use in regulating target genes. The application was filed on October 27, 2023, by inventors Thomas Blair Gainous, Xiao Yang, Giovanni Carosso, Lei S. Qi, and Daniel O. Hart, II.

Polyproline Nanocage Compound and Manufacturing Method

The USPTO has published a patent application for a polyproline nanocage compound and its manufacturing method. The application details a compound comprising two cyclic peptide scaffolds connected by molecules, with each scaffold containing polyproline helix rods and turn-angle molecules. This is a routine publication of a new patent application.

Heterodimeric Human IgG1 Polypeptides with Isoelectric Point Modifications

The USPTO has published a new patent application, US20260085132A1, titled 'Heterodimeric Human IgG1 Polypeptides with Isoelectric Point Modifications'. The application details methods for purifying desired heterodimer immunoglobulin variants from contaminating homodimer variants by modifying isoelectric points.

Patent Application: Bispecific Antibodies and Uses Thereof

The USPTO has published a new patent application (US20260085131A1) for bispecific antibodies and their uses. The application, filed on August 20, 2025, describes antibodies that bind to two different antigens with varying affinities.

Takeda's Monoclonal Antibody Inhibitor of Factor XIIa Patent Application

The USPTO has published a patent application from Takeda Pharmaceutical Company Limited for a monoclonal antibody inhibitor of Factor XIIa. The application, filed on August 12, 2025, describes methods for treating diseases associated with Factor XII, including hereditary angioedema and ocular diseases.

CD163 Binding Protein Patent Application

The USPTO has published a patent application (US20260085129A1) filed by ECO ANIMAL HEALTH LTD. on October 11, 2023. The application relates to an antibody that binds to porcine CD163, specifically its membrane-bound form.

Anti-CD157 Antibodies, Fragments, Compositions, and Methods

The USPTO has published a patent application (US20260085128A1) detailing anti-CD157 antibodies, antigen-binding fragments, compositions, and methods for their use. The application was filed on July 18, 2023, and describes potential diagnostic reagents and kits.

Bispecific Antibody Targets TIM-3 and CD39 for Cancer

The USPTO has published a patent application (US20260085127A1) for a bispecific antibody designed to target both TIM-3 and CD39 antigens. This antibody aims to enhance immune activity against cancer cells and is intended for cancer treatment.

Patent Application for Agonistic TNF Receptor Binding Agents

The USPTO has published a new patent application, US20260085126A1, for agonistic TNF receptor binding agents. The application, filed on August 27, 2025, by inventors including Ugur Sahin, details binding agents for TNF superfamily receptors and their potential medical uses.

Patent Application for Apelin Receptor Binding Polypeptides and Methods

The USPTO has published a new patent application (US20260085125A1) for apelin receptor binding polypeptides and methods of treatment. The application was filed on November 25, 2025, and details antibodies and polypeptides that specifically bind to the apelin receptor (APJ).

Patent Application for Tenosynovial Giant Cell Tumor Treatment

The USPTO has published a patent application (US20260085124A1) detailing compositions and methods for treating tenosynovial giant cell tumor using intra-articular delivery of anti-CSF1R antibodies. The application, filed by Kirk William Johnson, focuses on sustained drug exposure within joints.

Patent Application: Anti-FGFR2 Antibodies with Chemotherapy for Cancer Treatment

The USPTO has published patent application US20260085123A1, filed by Five Prime Therapeutics, Inc. The application details the use of anti-FGFR2 antibodies in combination with mFOLFOX6 chemotherapy for treating certain cancers.

Patent Application: Antibodies Binding Human 4Ig-B7H3

The USPTO has published a new patent application (US20260085122A1) filed by BeOne Medicines I GmbH. The application relates to antibodies or antigen-binding fragments thereof that bind to human 4Ig-B7H3.

Patent Application: Multispecific Binding Constructs Against Checkpoint Molecules

The USPTO has published a new patent application (US20260085121A1) from Compass Therapeutics, LLC, detailing multispecific binding constructs against checkpoint molecules. The application focuses on compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression, specifically blocking interactions between PD-1 and its ligand.

All-in-one Agonistic Antibodies Patent Application

The USPTO has published a patent application (US20260085113A1) filed by Hoffmann-La Roche Inc. on October 2, 2025. The application describes antigen binding molecules comprising biparatopic target-binding domains and cytokine receptor-binding domains designed to selectively activate cytokine receptors.

Patent Application for Free LIGHT Detection and Treatment

The USPTO has published a patent application (US20260085112A1) from Avalo Therapeutics, Inc. for methods of detecting and treating conditions associated with elevated free LIGHT using anti-LIGHT antibodies. The application covers methods for diagnosing conditions like acute lung injury, ARDS, and Crohn's Disease.

Patent Application for SLIT2 Related Compositions and Methods

The USPTO has published a new patent application (US20260085111A1) filed by EVEREST MEDICINES (SINGAPORE) PTE. LTD. The application relates to antibodies that bind to SLIT2 and related substitution mutants, including their manufacture and use.

Patent Application: Production Method for Product to Prevent Membrane Clogging

The USPTO has published a patent application from FUJIFILM Corporation detailing a production method for a product that aims to prevent membrane clogging during cell culture. The method involves specific mathematical expressions related to poloxamer concentration, product concentration, and hydrophobicity index to optimize the cell culture process.

Patent Application: Filtration Condition Evaluation and Cell Product Production

The USPTO has published a new patent application (US20260085109A1) from Asahi Kasei Life Science Corporation detailing a method for evaluating filtration conditions and producing cell products. The application was filed on November 14, 2023, and published with a projected application date of March 26, 2026.

Methods for Separating Chelator from Mixture Using Chromatography

The USPTO has published a new patent application, US20260085108A1, detailing methods for separating a chelator from a mixture using chromatography. This application, filed on September 8, 2023, by inventors Jason Huang and Qiang Li, describes techniques useful in adjusting the concentration of chelators in protein compositions.

Ginkgo Bioworks Patent for Protein Production and Secretion Systems

The USPTO has published a new patent application (US20260085107A1) filed by Ginkgo Bioworks, Inc. The patent describes expression systems for enhanced production and secretion of proteins, including specific examples like bovine lactoferrin. This application is part of the ongoing patent process for novel biotechnological methods.

Chimeric Antigen Receptor System for Signalling

The USPTO has published a new patent application, US20260085106A1, detailing a chimeric antigen receptor (CAR) system. This system is designed to control signalling based on the presence or absence of a specific agent, potentially impacting the development of targeted therapies.

MAGEA4 Specific T Cell Receptors Patent Application

The USPTO has published a patent application (US20260085105A1) filed by Amgen Inc. for recombinant T-cell receptors designed to selectively recognize MAGE-A4-derived peptides. The application details screening for cross-reactivity and alloreactivity.

Patent Application for Detecting Immune Cells Using Fusion Proteins

The USPTO has published a new patent application (US20260085104A1) detailing fusion proteins for detecting and isolating immune cells. The application, filed by Patrick Schlegel, describes specific fusion proteins involving a dysfunctional purinergic P2X7 receptor epitope and an antibody Fc region.

Long-acting insulin compound for treating diabetes

The USPTO has published a patent application (US20260085103A1) for a long-acting insulin compound designed for treating diabetes. The application details the compound's use in pharmaceutical compositions for conditions including type-I, type-II, and gestational diabetes.

Patent Application for Synthetic Promoters and Circuits in Cancer Cells

The USPTO has published a patent application (US20260085102A1) for nucleic acid molecules designed to specifically express sequences of interest in cancer cells. The application details synthetic promoters and circuits for use in cancer treatment.

Novel Platelet Derived Growth Factor Peptide Mimetic for Cardiac Repair

The USPTO has published a patent application (US20260085101A1) for a novel platelet-derived growth factor peptide mimetic designed for cardiac repair, particularly post-infarction. The application details specific compounds, their preparation, and methods of use.

US Patent Application for Antigen Production Methods

The USPTO has published a new patent application (US20260085100A1) from The Wistar Institute of Anatomy and Biology detailing methods for manufacturing individualized vaccines. The application focuses on nucleic acid molecules encoding neoantigens specific to tumor antigens for use in subject immunization.

Stabilized trimeric class I fusion proteins patent application

The USPTO has published a patent application (US20260085096A1) for stabilized trimeric class I fusion proteins. The application details specific mutations in the HR2 domain to enhance protein stability. This is a routine publication of a new patent application.

Patent Application for AAV Capsid Variants and Uses

The USPTO has published a new patent application (US20260085095A1) detailing adeno-associated virus (AAV) capsid variants and their uses. The application was filed on June 1, 2023, and is scheduled for publication on March 26, 2026. This represents a new disclosure in the field of gene therapy vectors.

Stapled Peptide and Use Thereof Patent Application

The USPTO has published a patent application (US20260085094A1) for a stapled peptide and its use, filed by inventors Zhixiang PAN, Haiying HE, Zhigan JIANG, and Shuhui CHEN. The application details a series of stapled peptides, specifically relating to polypeptides with sequences shown in formulas (I-1)-(I-5) and (II-6), and their pharmaceutically acceptable salts.

Melanocortin Receptor Ligands Patent Application

The USPTO has published a new patent application (US20260085092A1) for compounds acting as ligands for melanocortin receptors. The application details specific compounds and their potential use in treating mammals, filed by inventors Zeng Xin Dong and Jacques-Pierre Moreau.

Patent Application: Peptide Binds Trop2 for Cancer Treatment

The USPTO has published a patent application (US20260085091A1) from Kyungpook National University Industry-Academic Cooperation Foundation for a peptide that selectively binds to Trop 2. The peptide is intended for targeted therapeutic agents and anticancer drugs for resistant cancers such as breast, pancreatic, and cholangiocarcinoma.

Method for Reducing Host Cell Proteins in Affinity Chromatography

The USPTO has published a patent application from Genentech, Inc. detailing a method for purifying antibodies by reducing host cell proteins using a low conductivity aqueous solution in affinity chromatography. This application, filed on December 2, 2025, describes a specific purification technique for biopharmaceutical products.

Patent Application for Chromatographic Fractionation Method

The USPTO has published a new patent application (US20260085089A1) detailing a method and apparatus for continuous gradient elution chromatographic fractionation. The application, filed on September 12, 2023, describes a process for separating products of interest from impurities using chromatography matrices and elution solutions.

Method for preparing biologically active complexes using polypeptides and oleic acid

Method for preparing biologically active complexes using polypeptides and oleic acid

USPTO Patent Application: Antibody Drug Conjugate Comprising NMT Inhibitor

The USPTO has published a new patent application (US20260083858A1) related to antibody drug conjugates (ADCs) that comprise an NMT inhibitor conjugated to an antibody via a linker. The application details the inventors and abstract of the invention.

USPTO Patent Application for Anti-PD-1 Antibody-IL-2 Immunoconjugate Formulations

The USPTO has published a new patent application (US20260083857A1) for anti-PD-1 antibody-IL-2 immunoconjugate formulations. The application details stable pharmaceutical formulations comprising anti-human PD-1 antibody-modified human interleukin-2 immunoconjugates.